A Phase II Proof of Concept community infection study to assess the safety and potential efficacy of INNA-051.
Latest Information Update: 13 Feb 2025
Price :
$35 *
At a glance
- Drugs INNA-051 (Primary)
- Indications Influenza virus infections; Viral infections
- Focus Proof of concept; Therapeutic Use
- 10 Feb 2025 According to an Ena Respiratory media release, company received a US$5 million investment from Flu Lab and the investment will support ENA's planned Phase II proof-of-concept trial.
- 24 Jan 2025 New trial record
- 22 Jan 2025 According to the ENA Respiratory Media Release, company is currently planning Q4 2025 Phase II community infection study to assess the safety and potential efficacy of INNA-051 in reducing the incidence and duration of symptomatic infections caused by common respiratory viruses, including coronaviruses, seasonal influenza, rhinoviruses, respiratory syncytial virus and human metapneumovirus in young adults at risk for exposure living in the US.